Internal Medicine, Hematology & Oncology · Basking Ridge, NJ
NPI
1518200195
Since 2013
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
136 Mountainview Blvd
Basking Ridge, NJ, 07920
Phone (908) 542-3379
Groups this clinician bills Medicare through
Medicare paid, 2024
$32K
762 services
Medicare patients, 2024
102
Average age 72
Drug cost, 2024
$1.6M
553 prescriptions
Company payments, 2025
$103K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Victoria T Rizk was code 99215 (office e&m - established), 110 times for 47 patients. In total Victoria T Rizk billed 762 services in 18 codes, and Medicare paid $32K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 110 | 47 | $127.44 | $14K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 90 | 43 | $12.81 | $1,152 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 51 | 24 | $12.51 | $638 |
| 99215 Office E&M - Established | Facility | 49 | 20 | $108.45 | $5,314 |
| 99223 Hospital E&M - Initial | Facility | 25 | 24 | $134.79 | $3,370 |
| 99214 Office E&M - Established | Office | 18 | 16 | $97.57 | $1,756 |
| 99205 Office E&M - New | Office | 14 | 14 | $122.75 | $1,719 |
By year: 2022 $53K for 1,708 services; 2023 $84K for 2,546 services; 2024 $32K for 762 services.
Medicare prescription drug claims, 2024
In 2024, the drug Victoria T Rizk prescribed most often to Medicare patients was Anastrozole, with 103 prescriptions and refills. In total Victoria T Rizk wrote 553 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 103 | 303 | 39 | $2,355 |
| Imatinib Mesylate Generic | 40 | 42 | Under 11 | $8,363 |
| Kisqali Ribociclib Succinate | 27 | 27 | Under 11 | $417K |
| Ondansetron Odt Ondansetron | 26 | 26 | 20 | $573 |
| Letrozole Generic | 25 | 52 | Under 11 | $695 |
| Gabapentin Generic | 24 | 24 | Under 11 | $438 |
| Exemestane Generic | 23 | 68 | Under 11 | $3,602 |
| Keytruda Pembrolizumab | 22 | 23 | Under 11 | $271K |
| Tamoxifen Citrate Generic | 22 | 64 | Under 11 | $656 |
| Votrient Pazopanib Hcl | 17 | 17 | Under 11 | $213K |
| Eliquis Apixaban | 14 | 16 | Under 11 | $8,709 |
| Verzenio Abemaciclib | 14 | 14 | Under 11 | $201K |
| Olanzapine Odt Olanzapine | 12 | 18 | Under 11 | $500 |
| Sunitinib Malate Generic | 11 | 11 | Under 11 | $57K |
Brand drugs: - claims; generic drugs: 412 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Victoria T Rizk $103K ($103K in general payments such as food, travel and fees) from 15 companies. The largest payer was Gilead Sciences, Inc. with $75K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 72 | $75K |
| Lilly USA, LLC LLY | 31 | $17K |
| SpringWorks Therapeutics, Inc. | 6 | $5,752 |
| Novartis Pharmaceuticals Corporation NVS | 25 | $3,122 |
| Daiichi Sankyo Inc. 4568.T | 3 | $2,051 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $108 |
| BeOne Medicines USA, Inc. ONC | 1 | $94.57 |
| TerSera Therapeutics LLC | 3 | $90.53 |
| Seagen Inc. PFE | 1 | $72.73 |
| Pfizer Inc. PFE | 2 | $45.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.